The pace of development for CRISPR-based infectious disease assays increased as the pandemic progressed, more funding became available, and collaboration accelerated.
Early trial data of a Sanofi and GlaxoSmithKline SARS-CoV-2 vaccine indicates an insufficient immune response among older participants, according to Reuters.
Led by a group of 10 biopharmaceutical firms, the project will use Olink's proteomic technology to look at participants' plasma levels of roughly 1,500 proteins.
More than 198,000 LOF variants turned up in exome sequences from 49,960 UK Biobank participants, including variants with potential ties to human traits.
At its annual GPU conference this week, Nvidia said it is teaming with Oxford Nanopore, GSK, AstraZeneca, and PetaGene to advance bioinformatics and drug discovery.
The drugmaker will promote Zejula without a biomarker as a first-line maintenance option, and Myriad will highlight that patients with HRD are most likely to benefit.
